EU approves Sanofi’s Dupixent for the treatment of “light smokers”

Sanofi and partner Regeneron on Wednesday won European Union approval for wider use of the injectable drug Dupixent in patients with chronic lung disease, a rare case of the EU approving a drug faster than the US.

Teile diesen Beitrag: